Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Opus Group in conjunction with issuance of bonds
Mandate

Vinge advises Opus Group in conjunction with issuance of bonds

May 28, 2018 Capital Markets and Public M&A Automotive, Mobility and Electrification

Opus Group AB (publ) (”Opus”) has issued a so called senior unsecured bond in the amount of MSEK 500 MSEK with a term of four years on the Nordic market.

The bond, with a framework amount of MSEK 800, is subject to a variable interest rate of STIBOR 3m + 375 interest points and has a final maturity date in May 2022. The proceeds from the bond issue will primarily be used for refinancing Opus’ outstanding bond in the amount of MSEK 500 with a final maturity date on 20 November 2018 (ISIN: SE0005556834). Opus will apply for listing of the bond on Nasdaq Stockholm.

Vinge’s team consisted of partner Anders Strid together with, among others, associates Yohanna Öhrnegård and Lina André.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026